Question Bank › The streak is alive

The streak is alive

The streak is alive: management narrates back-to-back quarters of the same improvement and shows this quarter extended i

Calls Tested
444
Answered YES
38
Hit Rate
8.6%
rare by design

Xenia Hotels & Resorts, Inc. (XHR) — this company's answers

NO on the Q2 2022 call 2022-08-05 A
The model's full reasoning — Q2 2022 call → NOWe need answer YES or NO based on transcript. Need determine if management presents just-reported period as latest step in unbroken, still-running sequence of quarter-after-quarter improvement in same part of business, explicitly connecting this period to immediately preceding period(s) as one continuing climb, with real current-period evidence. We need parse transcript. Management discusses Q2 2022 results. They compare to 2019 and prior quarters. Key: "Momentum in our business picked up meaningfully since our last earnings call in early May. As we reported this morning, RevPAR grew 2% in the second quarter as compared to 2019, marking the first quarter since the onset of the pandemic where quarterly RevPAR exceeded the same period in 2019." That is first quarter above 2019, not necessarily consecutive improvement. They mention Q1 was 19.5% below 2019, Q2 2% above. That is improvement from Q1 to Q2, but is it "quarter-after-quarter improvement" sequence? They say "Momentum picked up meaningfully since last earnings call" and "substantial sequential improvement from first quarter". But is there a named improvement that has repeated across consecutive periods? They mention RevPAR growth vs 2019, but only Q2 is first above. They don't say "second consecutive quarter of improvement" or "another quarter of growth". They compare to 2019, not prior quarter. They do say "substantial sequential improvement from the first quarter" - that is one step, not repeated. Also "We are off to a solid start to the third quarter" with July preliminary. But that's forward. Need check if management explicitly connects this period to immediately preceding period(s) as one continuing climb. They say "Momentum in our business picked up meaningfully since our last earnings call" and "substantial sequential improvement from the first quarter". That is only one sequential improvement. No mention of multiple consecutive quarters. They also mention "first quarter since onset of pandemic where quarterly RevPAR exceeded 2019" - that's a milestone, not a streak. They don't say "another quarter of improvement" or "third consecutive". So likely NO. Also need consider other metrics: "Second quarter hotel EBITDA margin improved 365 basis points as compared to 2019" - not sequential. "Same-property hotel EBITDA for the quarter exceeded 2019 level by 15%" - again vs 2019. No chaining.

← Back to the full XHR analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — explicitly connecting this period to the immediately preceding period or periods as one continuing climb — with real, current-period evidence that the sequence extended again? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent pattern with all three of the following present: (1) A NAMED IMPROVEMENT THAT HAS NOW REPEATED ACROSS CONSECUTIVE PERIODS. Management identifies something specific about the business — such as orders, customers, volumes, output, utilization, activity, bookings, profitability, or the performance of a particular product, operation, or market — and describes it as having improved again this period on top of improvement in the immediately prior period or a run of recent consecutive periods. The chaining must be management's own sequential framing — for example, 'another quarter of growth,' 'our fourth consecutive quarter of...', 'improved again from last quarter,' 'each quarter this year has been stronger than the one before,' or equivalent language linking this period to the one(s) just before it. Comparisons made only against the year-ago period, or general claims of momentum without sequential linkage, do not qualify. (2) THE LATEST STEP IS REAL AND CURRENT. The extension of the streak in the just-reported period is grounded in things that actually happened — actual orders, sales, customers, volumes, shipments, activity, or results in this period described as above the prior period's level — not in forecasts, pipeline, or expectations of continued improvement. (3) MANAGEMENT TREATS THE SEQUENCE AS STILL RUNNING, DRIVEN BY SOMETHING OF THE COMPANY'S OWN. Management attributes the repeating improvement mainly to drivers attached to the company itself — its offering, customers, capabilities, capacity, or changes it made — that remain in force now, and conveys, directly or plainly in substance, that the sequence is continuing rather than concluded: the same drivers are still working, further steps are already forming, or the exit pace is at or above the period's level. Answer NO if the improvement is described only against the year-ago quarter or an easy comparison, with no explicit quarter-to-quarter chaining by management. NO if the period is presented as a single strong quarter, a rebound, or an inflection without a preceding consecutive run. NO if the streak is attributed mainly to external conditions — commodity prices, industry-wide shortage, restocking, pull-forward, seasonality, weather, or macro tailwinds — or to one-time events. NO if management itself signals the run is peaking, normalizing, or expected to pause. NO if the sequential improvement is only in cost cutting or shrinking losses on a declining business. NO if the streak framing appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
MNKD MannKind Corporation Q4 2023 2024-02-27 C
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
MFC Manulife Financial Corporation Q3 2023 2023-11-09 C+
BMBL Bumble Inc. Q3 2023 2023-11-07 F
GOLD Barrick Gold Corporation Q3 2023 2023-11-02 C
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
GRBK Green Brick Partners, Inc. Q3 2023 2023-11-01 B
TEL TE Connectivity Ltd. Q4 2023 2023-11-01 B
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
AEIS Advanced Energy Industries, Inc. Q2 2023 2023-08-03 B
PFIE Profire Energy, Inc. Q1 2023 2023-05-13 B
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
TSN Tyson Foods, Inc. Q2 2023 2023-05-08 D
CALX Calix, Inc. Q1 2023 2023-04-20 C+
TGT Target Corporation Q4 2022 2023-02-28 C
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
TOST Toast, Inc. Q4 2022 2023-02-16 C+
PI Impinj, Inc. Q4 2022 2023-02-08 B+
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
KFY Korn Ferry Q4 2022 2022-06-22 B
WRB W. R. Berkley Corporation Q1 2022 2022-04-26 B
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
ALHC Alignment Healthcare, Inc. Q3 2021 2021-11-06 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
PRPO Precipio, Inc. Q3 2018 2018-11-19 D
ALB Albemarle Corporation Q3 2018 2018-11-08 B
FMS Fresenius Medical Care AG & Co. KGaA Q2 2018 2018-07-31 C
ORAN Orange SA Q2 2018 2018-07-26 B
NOVT Novanta Inc. Q4 2017 2018-05-12 B+
EPC Edgewell Personal Care Company Q3 2017 2017-08-08 D
CNS Cohen & Steers, Inc. Q2 2017 2017-07-20 B
FNV Franco-Nevada Corporation Q3 2016 2016-11-08 B+
GES Guess?, Inc. Q1 2017 2016-05-25 F
SAN Banco Santander, S.A. Q4 2015 2016-01-27 B

How the model reasoned

MNKD · Q4 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES The transcript explicitly frames the just-reported quarter as the second consecutive (or second successive) profitable quarter for the endocrine business unit and for the Company overall. Management ties this directly to actual results in the current period (net income of $1 million GAAP and $7 million non-GAAP in Q4) following the prior 2023 quarter, and states they will continue to focus on growing the profitability of the endocrine business unit, which has had a positive contribution for two straight quarters.
CYBR · Q3 2021 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Udi Mokady explicitly frames Q3 as “another amazing quarter” that follows “an incredible second quarter,” using the single word “acceleration” to describe the quarter. He then quantifies the extension with concrete current-period metrics: subscription ARR growth accelerated to 131 % (reaching $139 million), total 38 % ARR growth (reaching $344 million), recurring revenue growth accelerated to 41 % ($89 million), and new logos accelerated to over 230.
MFC · Q3 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Roy Gori explicitly frames core ROE as having been ahead of the 15%+ medium-term target for the second consecutive quarter, while noting a 35% rise in core EPS this quarter (on top of steady year-on-year growth in core earnings over the past three quarters). Colin reinforces the sequential nature by stating that core ROE “increase[d] to 16.8%” this quarter.

More from the question bank

Stretched by business that already arrivedMoney already collected for work not yet donActed like it's already biggerRepeat customers are now the ones asking forThe knock on the company is going staleWhere the money wentAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.